Rucaparib-d8

Rucaparib-d8
Artikelnummer
MEXHY-10617AS-0
Verpackungseinheit
Get quote
Hersteller
MedChemExpress

Verfügbarkeit: wird geladen...
Preis wird geladen...
Product Description: Rucaparib-d8 (AG014699-d8 ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a Ki of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research[1][2][3][4].

Applications: Cancer-programmed cell death

Formula: C19H10D8FN3O

References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15(4), 1241-1249./[3]Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6(3), 945-956./[4]Hunter JE, et al. NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31(2), 251-264./[5]Matt Shirley, et al. Rucaparib: A Review in Ovarian Cancer. Target Oncol. 2019 Apr;14(2):237-246./[6]J Murray, et al. Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules. Br J Cancer. 2014 Apr 15;110(8):1977-84./[7]Jianneng Li, et al. Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Sci Transl Med. 2021 May 26;13(595):eabe8226.

Molecular Weight: 331.41

Research Area: Cancer

Target: Isotope-Labeled Compounds;PARP
Mehr Informationen
Artikelnummer MEXHY-10617AS-0
Hersteller MedChemExpress
Hersteller Artikelnummer HY-10617AS-0
Verpackungseinheit Get quote
Mengeneinheit STK
Produktinformation (PDF)
×
MSDS (PDF)
×